This was CUO 23 – Photos & Videos Live Stream CUO 23 - The Video with interviews! 15 views Videos Can we make NMIBC treatment better tolerated and cheaper, B. Pradere, FR Can we treat beyond guidelines, M. Schmidinger, AUT Circulating tumor DNA for biomarker dectection in patients with CRPC – ready for prime time, T. Bauernhofer, AUT Enbloc for NMIBC – Where we stand now, D. Enikeev, RU Essentials of pheochromocytoma and adrenocortocal carcinoma, M. Remzi, AUT How to best use current drugs/ treatment sequencing and combinations for metastatic castration resistant prostate cancer, G. Kramer, AUT HPV vaccination – a gender neutral cancer prevention strategy, E. Joura, AUT Intensifiing treatments for mHSPC, I. Heidegger, AUT Is there a role for triplet therapy in the first-line setting of mRCC, M. Schmidinger, AT Management of clinically node positive prostate cancer, J. Bektic, AUT MicroRNAs as diagnostic bio- markers in testicular cancer, M. Pichler, AUT Next generation therapies in NMIBC, F.Soria,IT Open surgical aspects of different urinary diversions/ pros & cons, S. Ahyai, AUT Patient reported outcomes and perspectives in cancer surgery and therapy, M. Leitsmann, AUT Patient selection for adjuvant therapy in RCC, D. Niedersüß, AUT Prostate cancer risk, screening and management in patients with germline BRCA1_2 mutations, P. Rajwa, PL Recent Developments in Bladder Pathology, A. Oszwald, AT Keynote Lecture, To know cancer is to defeat cancer/ lessons from precision medicine, W. Berger, AUT Bladder preservation after neo-adjuvant chemotherapy/ possible today, M. Moschini, IT Cytoreduction in mRCC/ who, how, when? H. Fajkovic, AUT Sequencing systemic therapies and looking to the horizon for metastatic urothelial carcinoma, C. Mir, ESP Welcome Partner Principal Partner Gold Partner Silver Partner Bronze Partner Pop-Up Partner Special Partner (c) 2023 CUO | Impressum & Privacy Policy